Michael Mandola
About Michael Mandola
Michael Mandola is the Executive Director, Development Program Lead, Oncology Clinical Development at Bristol Myers Squibb and a member of the Strategic Innovation Board at The Max Foundation.
Company
Michael Mandola is currently working at Bristol Myers Squibb as the Executive Director, Development Program Lead in Oncology Clinical Development. Additionally, he serves as a Member of the Strategic Innovation Board at The Max Foundation, where he contributes to innovative strategies for cancer treatment.
Title
At Bristol Myers Squibb, Michael Mandola holds the title of Executive Director, Development Program Lead in Oncology Clinical Development. His role involves leading clinical development programs and initiatives focused on oncology.
Education and Expertise
Michael Mandola earned his PhD in Molecular Biology from Rutgers University, completing his studies from 2000 to 2004. He also holds a BS in Biology from Stockton University, where he studied from 1996 to 2000. His expertise lies in molecular biology and oncology, which has been enhanced through his extensive research and leadership roles.
Background
Michael Mandola has a diverse background in molecular biology and oncology. He completed postdoctoral fellowships at The Cancer Institute of New Jersey and Fox Chase Cancer Center, specializing in molecular biology and oncology. His career also includes significant leadership roles at Nucleus Global and Bristol Myers Squibb.
Achievements
Michael Mandola has held multiple leadership roles at Bristol Myers Squibb since joining the company in 2017. He was the President of US Operations at Nucleus Global for over a decade, where he oversaw substantial growth and development. He also contributed to clinical trial leadership and global medical directorship at Bristol Myers Squibb.